Samsung Bioepis Herceptin biosimilar approved in EU
Mylan and Biocon resolve biosimilar manufacturing issues
X
Samsung Bioepis Herceptin biosimilar approved in EU
https://pharmaphorum.com/news/samsung-bioepis-herceptin-biosimilar-approved-eu/
biosimilar
EU regulators back Avastin biosimilar
But launch unlikely until 2022
Roche MS drug sales rise, but so does biosimilar threat
Ocrevus shines as biosimilars bite in Europe
Payday for AbbVie as Humira biosimilar delayed for five years
Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
Pfizer sues J&J, alleging it blocked access to Remicade biosimilar
J&J used anticompetitive tactics to prevent use of cheaper Inflectra
Roche under pressure as second rituximab biosimilar filed in US
Sandoz is following closely behind rival from Teva and Celltrion.
Mylan/Biocon Herceptin biosimilar faces EU delay
EU inspectors require re-inspection of Bangalore plant.
Genentech’s subcutaneous rituximab approved in US
Subcutaneous version gives more convenient injection lasting minutes, rather than several hours.